EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers

Lucy M Carter iD, Zoe Wigston, Philip Laws, Edward M Vital iD

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Lucy M Carter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lupus UK, National Institute for Health and Care Research, Department of Health and Social Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Observations with rituximab suggest B-cell independent mechanisms of cutaneous lupus erythematosus (CLE) in systemic lupus erythematosus (SLE), especially discoid lupus erythematosus (DLE). Type-I interferon receptor blockade with anifrolumab shows efficacy in SLE, but efficacy for cutaneous disease of specific morphologies has not been studied. Interferon has pleotropic immune effects and it is unknown which of these are critical to therapeutic response.

Objectives

We evaluated clinical efficacy and quality-of-life impact of type-I interferon-blockade in: (i) rituximab-refractory CLE; (ii) DLE and other morphologies and (iii) transcriptomic and flow cytometric biomarkers.

Methods

We conducted a prospective single-centre study of anifrolumab in refractory mucocutaneous SLE. CLE Disease Area and Severity Index (CLASI) activity score, health-related quality of life, 96-probe TaqMan® gene expression analysis capturing key SLE blood transcriptome signatures, and eight-colour flow cytometry were undertaken at baseline, 1, 3 and 6 months.

Results

Seven patients [DLE (n = 5), chilblain lupus erythematosus (n = 1), subacute CLE (n = 1)] were evaluated. The median number of prior therapies was six (range 3–15), including rituximab in six of seven patients. Median CLASI-A showed rapid and sustained improvement from 17 at baseline to 6 (P = 0.016) at 1 month and 0 (P < 0.001) by 3 months. The median percentage reduction in CLASI-A at 3 months was 60%. Significant improvements were observed in Dermatology Life Quality Index scores (P < 0.001), EuroQol 5D visual analogue scale (P = 0.002) and LupusQoL fatigue, image and planning domains (P ≤ 0.05). One patient discontinued treatment owing to severe herpes zoster. Clinical responses paralleled discrete suppression of interferon-stimulated genes (ISGs) from SLE blood transcriptome module M1.2 with more varied downregulation in other interferon modules. Myeloid and inflammation-annotated genes remained upregulated throughout treatment. Intermediate monocytes (CD14++CD16+) reduced to normal levels during therapy (P = 0.014), while other flow subsets showed no substantive changes.

Conclusions

These data indicate rapid efficacy of anifrolumab in DLE and rituximab-resistant CLE. Response is associated with suppression of a subset of ISGs and decline in intermediate monocytes. Suppression of all ISGs or the wider SLE blood transcriptome is not required for response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, CutaneousLupus Erythematosus, DiscoidLupus Erythematosus, SystemicHumansTranscriptomeRituximabProspective StudiesQuality of LifeGene Expression ProfilingBiomarkersInterferonsAntibodies, Monoclonal, Humanized

Substanzen

RituximabBiomarkersInterferonsanifrolumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • NIHR Leeds Biomedical Research Centre.
  • Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

ORCID-Profile: Lucy M Carter, Edward M Vital

Förderung

  • Lupus UK
  • National Institute for Health and Care Research
  • Department of Health and Social Care

Zitieren

APA

Carter, L. M., Wigston, Z., Laws, P., & Vital, E. M. (2023). Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad089

Vancouver

Carter LM, Wigston Z, Laws P, Vital EM. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad089

BibTeX
@article{Carter2023,
  author = {Carter, Lucy M and Wigston, Zoe and Laws, Philip and Vital, Edward M},
  title = {Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad089}
}
Kostenlos starten →